Upregulation of glutathione peroxidase-1 expression and activity by glial cell line-derived neurotrophic factor promotes high-level protection of PC12 cells against 6-hydroxydopamine and hydrogen peroxide toxicities

Rejuvenation Research

Volumn 16, Issue 3, 2013, Pages 185-199

  Gharib, Ehsan ^a,b,c   Gardaneh, Mossa ^a   Shojaei, Sahar ^a  

^a NATIONAL INSTITUTE OF GENETIC ENGINEERING AND BIOTECHNOLOGY   (Iran)

^b UNIVERSITY OF TEHRAN   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTATHIONE PEROXIDASE 1; HYDROGEN PEROXIDE; LENTIVIRUS VECTOR; OXIDOPAMINE;

ANIMAL CELL; ARTICLE; ASTROCYTE; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; GENE EXPRESSION; NONHUMAN; PC12 CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SURVIVAL RATE; UPREGULATION; VECTOR CONTROL; WILD TYPE;

ANIMALS; BASE SEQUENCE; DNA PRIMERS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; GLUTATHIONE PEROXIDASE; HEK293 CELLS; HUMANS; HYDROGEN PEROXIDE; NEUROGLIA; OXIDOPAMINE; PC12 CELLS; POLYMERASE CHAIN REACTION; RATS; UP-REGULATION;

LENTIVIRUS; RATTUS;

EID: 84879117143     PISSN: 15491684     EISSN: 15578577     Source Type: Journal    
DOI: 10.1089/rej.2012.1390     Document Type: Article

References (34)

1. Hirsch EC, Faucheux B, Damier P, Mouatt-Prigent A, Agid Y. Neuronal vulnerability in Parkinson's disease. J Neural Transm 1997;Suppl 50:79-88.
2. Ziv I, Barzilai A, Offen D, Nardi N, Melamed E. Nigrostriatal neuronal death in Parkinson's disease-a passive or an active genetically-controlled process? J Neural Transm 1997;Suppl 49:69-76.
3. Lang AE, Obeso JA. Challenges in Parkinson's disease: Restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 2004;3:309-316.
4. Bjö rklund A, Kirik D, Rosenblad C, Georgievska B, Lundberg C, Mandel RJ. Towards a neuroprotective gene therapy for Parkinson's disease: Use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res 2000;886:82-98.
5. Yacoubian TA, Standaert DG. Targets for neuroprotection in Parkinson's disease. Biochim Biophys Acta 2009;1792:676-687.
6. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, McBride J, Chen EY, Palfi S, Roitberg BZ, Brown WD, Holden JE, Pyzalski R, Taylor MD, Carvey P, Ling Z, Trono D, Hantraye P, Déglon N, Aebischer P. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000; 290:767-773.
7. Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, Bunnage M, Brooks DJ, Svendsen CN, Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003;9:589-595.
8. Sherer TB, Fiske BK, Svendsen CN, Lang AE, Langston JW. Crossroads in GDNF therapy for Parkinson's disease. Mov Disord 2006;21:136-141.
9. Love S, Plaha P, Patel NK, Hotton GR, Brooks DJ, Gill SS. Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nature 2005;11:703-704.
10. Zhou C, Huang Y, Przedborski S. Oxidative stress in Parkinson's disease. Ann NY Acad Sci 2008;1147:93-104.
11. Halliwell B. Oxidative stress and neurodegeneration: Where are we now? J Neurochem 2006;97:1634-1658.
12. Halliwell B, Gutteridge JM. Biologically relevant metal iondependent hydroxyl radical generation. An update. FEBS Lett 1992;307:108-112.
13. Cheng W, Fu YX, Porres JM, Ross DA, Lei XG. Selenium-dependent cellular glutathione peroxidase protects mice against a pro-oxidant-induced oxidation of NADPH, NADH, lipids, and protein. FASEB J 1999;13: 1467-1475.
14. Cheng WH, Ho YS, Valentine BA, Ross DA, Combs GFJ, Lei XG. Cellular glutathione peroxidase is the mediator of body selenium to protect against paraquat lethality in transgenic mice. J Nutr 1999;128:1070-1076.
15. Bensadoun J, Mirochnitchenko O, Inouye M, Aebischer P, Zurn AD. Attenuation of 6-OHDA induced neurotoxicity in glutathione peroxidase transgenic mice. Eur J Neurosci 1998;10:3231-3236.
16. Klivenyi P, Andreassen OA, Ferrante RJ, Dedeoglu A, Mueller G, Lancelot E, Bogdanov M, Andersen JK, Jiang D, Beal MF. Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine. J Neurosci 2000;20:1-7.
17. Thiruchelvam M, Prokopenko O, Cory-Slechta DA, Buckley B, Mirochnitchenko O. Overexpression of superoxide dismutase or glutathione peroxidase protects against the paraquat + maneb-induced Parkinson disease phenotype. J Biol Chem 2005;280:22530-22539.
18. Ridet JL, Bensadoun JC, Déglon N, Aebischer P, Zurn AD. Lentivirus-mediated expression of glutathione peroxidase: Neuroprotection in murine models of Parkinson's disease. Neurobiol Dis 2006;21:29-34.
19. Sandhu JK, Gardaneh M, Iwasiow R, Lanthier P, Gangaraju S, Ribecco-Lutkiewicz M, Tremblay R, Kiuchi K, Sikorska M. Astrocyte-secreted GDNF and glutathione antioxidant system protect neurons against 6OHDA cytotoxicity. Neurobiol Dis 2009;33:405-414.
20. Safi R, Gardaneh M, Panahi Y, Maghsoudi N, Zaefizadeh M, Gharib E. Optimized quantities of GDNF overexpressed by engineered astrocytes are critical for protection of neuroblastoma cells against 6-OHDA toxicity. J Mol Neurosci 2012;46:654-665.
21. Gardaneh M, Gholami M, Maghsoudi N. Synergy between glutathione peroxidase-1 and astrocytic growth factors suppresses free radical generation and protects dopaminergic neurons against 6-hydroxydopamine. Rejuven Res 2011;14:195-204.
22. Chao CC, Lee EHY. Neuroprotective mechanism of glial cell line-derived neurotrophic factor on dopamine neurons: Role of anti-oxidation. Neuropharmacology 1999;38:913-916.
23. St. Clair DK, Chow CK. Glutathione peroxidase: Activity and steady-state level of mRNA. In: Punchard NA, Kelly FJ, eds. Free Radicals. IRL Press, Oxford, 1996, pp. 227-240.
24. Browne RW, Armstrong D Reduced glutathione and glutathione disulfide. In: Armstrong D, ed. Free Radical and Anti-oxidant Protocols. Humana Press, Totowa, NJ, 1998, pp. 347-352.
25. Petit PX, Lecoeur H, Zorn E, Dauguet C, Mignotte B, Gougeon ML. Alterations in mitochondrial structure and function are early events of dexamethasone-induced thymocyte apoptosis. J Cell Biol 1995;130:157-167.
26. Unsicker K, Meyer V, Flanders KC, Wirth SB, Rufer M, Krieglstein K, Suter-Crazzolara, C. Growth factors as products and regulators of astrocytes: CNTF, FGF, TGF-b1-3, and GDNF. Eur Neuropsychopharmacol 1995;5:223-223.
27. Oh-hashi K, Ito M, Tanaka T, Hirata Y, Kiuchi K. Biosynthesis, processing, and secretion of glial cell line-derived neurotrophic factor in astroglial cells. Mol Cell Biochem 2009;323:1-7.
28. Smythies J, Galzigna L. The oxidative metabolism of catecholamines in the brain: A review. Biochim Biophys Acta 1998;1380:159-162.
29. Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 1989;52:1830-1836.
30. Zhang J, Perry G, Smith MA, Robertson D, Olson SJ, Graham DG, Montine TJ. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol 1999;154:1423.
31. Walkinshaw G, Waters CM. Neurotoxin-induced cell death in neuronal PC12 cells is mediated by induction of apoptosis. Neuroscience 1994;63:975-987.
32. Blum D, Wu Y, Nissou MF, Arnaud S, Alim-Louis-Benabid, Verna JM. p53 and Bax activation in 6-hydroxydopamineinduced apoptosis in PC12 cells. Brain Res 1997;751:139-142.
33. Hanrott, K., Gudmunsen, L., O'Neill, M. J., and Wonnacott, S. 6-Hydroxydopamine-induced apoptosis is mediated via extra cellular auto-oxidation and caspase 3-dependent activation of protein kinase Cdelta. J Biol Chem 2006;281:5373-5382.
34. Soto-Otero R, Méndez-Alvarez E, Hermida-Ameijeiras A, Muñ oz-Patiñ o AM, Labandeira-Garcia JL. Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: Potential implication in relation to the pathogenesis of Parkinson's disease. J Neurochem 2000;74: 1605-1612.